Abstract
One of the consistent findings in the brains of Alzheimers Disease (AD) patients is loss of cholinergic function. The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacological intervention to increase cholinergic transmission. The cognitive effects of acetylcholine are mediated via the muscarinic M1 receptor. Direct stimulation of this receptor using muscarinic M1 agonists improves cognition in animal models and improves performance in cognitive tests in Alzheimers patients. Alternatively, antagonists of central presynaptic M2 receptors improves cognition by increasing the central release of acetylcholine. Both approaches require high selectivity for one muscarinic receptor sub-type both for efficacy and to avoid cholinergic side effects. In this review summarizes recent progress in the identification and characterization of selective muscarinic receptor ligands for the treatment of Alzheimers disease.
Keywords: alzheimers disease, cognition, muscarinic receptor
Current Pharmaceutical Design
Title: Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease
Volume: 11 Issue: 26
Author(s): J. W. Clader and Y. Wang
Affiliation:
Keywords: alzheimers disease, cognition, muscarinic receptor
Abstract: One of the consistent findings in the brains of Alzheimers Disease (AD) patients is loss of cholinergic function. The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacological intervention to increase cholinergic transmission. The cognitive effects of acetylcholine are mediated via the muscarinic M1 receptor. Direct stimulation of this receptor using muscarinic M1 agonists improves cognition in animal models and improves performance in cognitive tests in Alzheimers patients. Alternatively, antagonists of central presynaptic M2 receptors improves cognition by increasing the central release of acetylcholine. Both approaches require high selectivity for one muscarinic receptor sub-type both for efficacy and to avoid cholinergic side effects. In this review summarizes recent progress in the identification and characterization of selective muscarinic receptor ligands for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Clader W. J. and Wang Y., Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease, Current Pharmaceutical Design 2005; 11 (26) . https://dx.doi.org/10.2174/138161205774370762
DOI https://dx.doi.org/10.2174/138161205774370762 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Effect of Cholinergic Stimulation in Early Alzheimers Disease - Functional Imaging During a Recognition Memory Task
Current Alzheimer Research Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology Subject Index to Volume 1
Current Pharmacogenomics The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology DNA Double Strand Breaks: A Common Theme in Neurodegenerative Diseases
Current Alzheimer Research Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews Benefit of 13-desmethyl Spirolide C Treatment in Triple Transgenic Mouse Model of Alzheimer Disease: Beta-Amyloid and Neuronal Markers Improvement
Current Alzheimer Research Prescription Opioid Abuse and its Potential Role in Gross Dental Decay
Current Drug Safety Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry The Challenge of microRNA as a Biomarker of Epilepsy
Current Neuropharmacology Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Reducing Sexual Communication Anxiety of Women Upon Marriage: A Randomized Quasi-experimental Study from Iran
Current Women`s Health Reviews Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews